Drug firm Lupin Monday said it has received approval from the US health regulator to market Sildenafil tablets, used in the treatment of erectile dysfunction, in the American market.
The company has received the approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version of Pfizer Inc's Viagra tablets, Lupin Ltd said in a regulatory filing.
The Mumbai-based company has received approval for its product in various strengths, it added.
Sildenafil tablets are a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED).
According to IQVIA MAT December 2018 data, Sildenafil tablets USP, 25 mg, 50 mg, and 100 mg had annual sales of around USD 611 million in the US market.
Lupin's shares were trading 1.73 per cent down at Rs 730.65 apiece on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app